Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Non-Current Assets (2016 - 2025)

Dare Bioscience (DARE) has disclosed Non-Current Assets for 11 consecutive years, with $5.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets rose 84.56% year-over-year to $5.7 million, compared with a TTM value of $22.6 million through Sep 2025, up 78.31%, and an annual FY2024 reading of $3.7 million, down 2.28% over the prior year.
  • Non-Current Assets was $5.7 million for Q3 2025 at Dare Bioscience, down from $6.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $6.8 million in Q1 2025 and bottomed at $511161.0 in Q4 2021.
  • Average Non-Current Assets over 5 years is $2.5 million, with a median of $1.4 million recorded in 2022.
  • Peak annual rise in Non-Current Assets hit 374.67% in 2023, while the deepest fall reached 37.58% in 2023.
  • Year by year, Non-Current Assets stood at $511161.0 in 2021, then skyrocketed by 54.09% to $787630.0 in 2022, then skyrocketed by 374.67% to $3.7 million in 2023, then fell by 2.28% to $3.7 million in 2024, then skyrocketed by 57.24% to $5.7 million in 2025.
  • Business Quant data shows Non-Current Assets for DARE at $5.7 million in Q3 2025, $6.4 million in Q2 2025, and $6.8 million in Q1 2025.